Drug intelligence / Profile preview

BCMA Nanobody CAR-T

Development stage: Preclinical
Lead developer: Hebei Taihe Chunyu Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCMA Nanobody CAR-T is a cell therapy under evaluation for the treatment of relapsed/refractory multiple myeloma. It consists of T-cells engineered with a chimeric antigen receptor (CAR). This CAR is designed with a BCMA nanobody as the antigen-binding domain, a CD8 hinge, a transmembrane region, and a 4-1bb co-stimulation domain. The therapy aims to target and eliminate myeloma cells that extensively express B-cell maturation antigen (BCMA), a protein involved in plasma cell proliferation and survival.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on BCMA Nanobody CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCMA Nanobody CAR-T.

Explore the full profile